Data_Sheet_1_High-Dose Dexamethasone Alters the Increase in Interleukin-16 Level in Adult Immune Thrombocytopenia.PDF

Adult primary immune thrombocytopenia (ITP) is an autoimmune-mediated haemorrhagic disorder. Interleukin-16 (IL-16) can directly affect cellular or humoural immunity by mediating the cellular cross-talk among T cells, B cells and dendritic cells. Several studies have focused on IL-16 as an immunomodulatory cytokine that takes part in Th1 polarization in autoimmune diseases. In this study, we investigated IL-16 expression in the bone marrow supernatant and plasma of ITP patients and healthy controls. What's more, we detected IL-16 expression in ITP patients with the single-agent 4-day high-dose dexamethasone (HD-DXM) therapy. In patients with active ITP, bone marrow supernatant and plasma IL-16 levels increased (P < 0.05) compared with those of healthy controls. In the meantime, the mRNA expression in BMMCs (pro-IL-16, caspase-3) and PBMCs (pro-IL-16, caspase-3 and T-bet) of ITP patients was increased (P < 0.05) relative to those of healthy controls. In patients who responded to HD-DXM therapy, both plasma IL-16 levels and gene expression in PBMCs (pro-IL-16, caspase-3, and T-bet) were decreased (P < 0.05). In summary, the abnormal level of IL-16 plays important roles in the pathogenesis of ITP. Regulating Th1 polarization associated with IL-16 by HD-DXM therapy may provide a novel insight for immune modulation in ITP.

成人原发性免疫性血小板减少症（ITP）是一种由自身免疫介导的出血性疾病。白细胞介素-16（IL-16）能够通过介导T细胞、B细胞和树突状细胞之间的细胞间通讯，直接影响细胞或体液免疫。众多研究已聚焦于IL-16作为一种免疫调节性细胞因子，其在自身免疫性疾病中的Th1极化过程中发挥重要作用。在本研究中，我们探讨了ITP患者与健康对照者的骨髓上清液和血浆中IL-16的表达情况。此外，我们还检测了接受单剂4天高剂量地塞米松（HD-DXM）治疗的ITP患者体内的IL-16表达。在活动性ITP患者中，与健康对照组相比，骨髓上清液和血浆中的IL-16水平显著升高（P < 0.05）。与此同时，ITP患者的骨髓单个核细胞（BMMCs）中（前体IL-16、caspase-3）和外周血单个核细胞（PBMCs）中（前体IL-16、caspase-3和T-bet）的mRNA表达亦显著升高（P < 0.05）。在响应HD-DXM治疗的患者中，血浆IL-16水平以及PBMCs中的基因表达（前体IL-16、caspase-3、T-bet）均显著降低（P < 0.05）。总之，IL-16水平的异常在ITP的发病机制中扮演着至关重要的角色。通过HD-DXM疗法调节与IL-16相关的Th1极化，可能为ITP的免疫调节提供新的见解。